DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Relenza (Zanamivir) - Published Studies

 
 



Relenza Related Published Studies

Well-designed clinical trials related to Relenza (Zanamivir)

Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. [2010.11.02]

A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. [2008.01]

Efficacy and Safety of Inhaled Zanamivir in the Prevention of Influenza in Community-Dwelling, High-Risk Adult and Adolescent Subjects: A 28-day, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. [2007.08]

Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. [2003.06]

Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. [2003]

Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. [2002.12.01]

The effect of zanamivir treatment on the early immune response to influenza vaccination. [2001.09.14]

Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. [2001.03.10]

Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. [2000.11.02]

Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation. [2000.07]

Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. [2000.06]

Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. [2000.05]

Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. [2000.04]

Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. [2000.03]

A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration. [2000.03]

Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group. [2000.02]

Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. [2000.02]

Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. [2000.01]

Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. [1999.11]

Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. [1999.09]

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. [1999.08]

Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. [1999.07.07]

Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. [1999.07]

Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection. [1999]

Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group. [1999]

Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. [1999]

Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. [1999]

Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. [1998.11]

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. [1997.09.25]

Well-designed clinical trials possibly related to Relenza (Zanamivir)

Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial. [2013]

Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). [2012]

Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. [2010.11.15]

Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. [2010.11]

Neuraminidase inhibitors for influenza treatment and prevention in healthy adults. [2010.08.01]

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. [2010.06]

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. [2010]

Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. [2010]

Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. [2009.10.06]

Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. [2005.10]

Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. [2001.09.24]

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. [1999.10.06]

Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza. [1997.12]

Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. [1996.01.24]

Other research related to Relenza (Zanamivir)

Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. [2014]

Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. [2011.09.01]

An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults. [2011.09]

Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. [2011.07]

Influenza neuraminidase-inhibiting antibodies are induced in the presence of zanamivir. [2011.03.21]

Successful salvage therapy with inhaled zanamivir in a patient with peramivir-resistant pandemic influenza A (H1N1) 2009 virus. [2011.02]

Quantification of the anti-influenza drug zanamivir in plasma using high-throughput HILIC-MS/MS. [2011.01]

Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. [2011.01]

Household transmission of influenza (H1N1-2009) in Japan: age-specificity and reduction of household transmission risk by zanamivir treatment. [2011]

Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. [2010.06.01]

Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. [2010.05.01]

A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. [2010.03.05]

Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. [2009.12.15]

Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. [2009.02]

Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques. [2008.11]

Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. [2008.10]

Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. [2008.08.01]

Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. [2007]

[Nosocomial outbreak of influenza in high-risk hematological patients. Efficacy of control measures and the use of zanamivir] [2006.01]

Inhaled Zanamivir Versus Placebo for the Prevention of Influenza Outbreaks in an Unvaccinated Long-term Care Population. [2005.11]

Inhaled Zanamivir Versus Rimantadine for the Control of Influenza in a Highly Vaccinated Long-term Care Population. [2005.11]

Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo. [2005.06.02]

Zanamivir: an influenza virus neuraminidase inhibitor. [2005.04]

[Neuraminidase inhibitors oseltamivir and zanamivir: new means of defence against influenza] [2004.01.10]

Zanamivir in the treatment of influenza. [2003.05]

Compared protective effect of nasal immunoprophylaxis using a new human monoclonal IgM antibody, human polyclonal antibodies, F(ab')2, amantadine, and zanamivir for prophylaxis of influenza A virus pneumonia in mice. [2003.03]

Bedside rapid flu test and zanamivir prescription in healthy working adults: a cost-benefit analysis. [2003]

[Patient assessment for zanamivir therapy (second report) -- a survey of patients with influenza who were prescribed zanamivir during the 2001/2002 season in Japan] [2002.12]

Drug under test: influenza--Relenza in daily practice. Experience during the influenza season 1999/2000. [2002.12]

Efficacy and safety of zanamivir in patients with influenza--impact of age, severity of infections and specific risk factors. [2002.12]

The effect of zanamivir treatment on influenza complications: a retrospective cohort study. [2002.11]

Risk for respiratory events in a cohort of patients receiving inhaled zanamivir: a retrospective study. [2002.11]

Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing care population. [2002.10]

The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. [2002.01]

Patient perspective on zanamivir in the treatment of influenza. [2002.01]

Formoterol: a review of its use in chronic obstructive pulmonary disease. [2002]

Zanamivir is an effective treatment for influenza in children undergoing therapy for acute lymphoblastic leukemia. [2002]

Zanamivir: an update of its use in influenza. [2002]

Zanamivir: an alternative translation. [2001.12.29]

Clinical effectiveness and cost effectiveness of zanamivir (Relenza): translating the evidence into clinical practice, a National Institute for Clinical Excellence view. [2001.12.29]

Zanamivir: from drug design to the clinic. [2001.12.29]

Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. [2001.10]

[Patient assessment for zanamivir therapy--a survey of patients with influenza who were prescribed zanamivir during the 2000/2001 season in Japan] [2001.09]

Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. [2001.04]

Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. [2001.04]

Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza. [2001.03]

[Efficacy of inhaled zanamivir in the treatment and prevention of influenza] [2001.02]

Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. [2001.01.22]

Neuraminidase inhibitors: zanamivir and oseltamivir. [2001.01]

Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications. [2001]

Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. [2001]

Zanamivir: a rational approach to influenza B. [2001]

Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. [2000.11.27]

Effect of zanamivir on duration and resolution of influenza symptoms. [2000.11]

Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. [2000.11]

Zanamivir in the treatment and prevention of influenza. [2000.06]

Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. [2000.01]

Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract. [1999.11]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014